What is CRISPR Therapeutics AG Intrinsic Value: Projected FCF?
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for CRISPR Therapeutics AG's Intrinsic Value: Projected FCF or its related term are showing as below:
CRSP'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 3.11 Med: 4.11 Max: 10.23
Current: 8.78
During the past 10 years, the highest Price-to-Intrinsic-Value-Projected-FCF of CRISPR Therapeutics AG was 10.23. The lowest was 3.11. And the median was 4.11.
CRSP's Price-to-Projected-FCF is ranked worse than 87.68% of 203
companies
in the Biotechnology industry
Industry Median: 2.39
vs CRSP: 8.78
CRISPR Therapeutics AG Intrinsic Value: Projected FCF Historical Data
The historical data trend for CRISPR Therapeutics AG's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
CRISPR Therapeutics AG Intrinsic Value: Projected FCF Chart
Competitive Comparison of CRISPR Therapeutics AG's Intrinsic Value: Projected FCF
For the Biotechnology subindustry, CRISPR Therapeutics AG's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG's Price-to-Projected-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Price-to-Projected-FCF falls into.
CRISPR Therapeutics AG Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (NAS:CRSP) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
CRISPR Therapeutics AG's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
53.73
/
6.1171393496011
=
8.78
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG Intrinsic Value: Projected FCF Related Terms
Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRSP has been successfully added to your 